Power Law company profile

Blueprint Medicines

Biotech & Life Sciences · Cambridge, United States · Founded 2011 · IPO 2015 Unicorn

Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases

Valuation

$8.25B

Market cap · 2026

Revenue

$509M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

7 investors on Blueprint Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

F-Prime

Third Rock Ventures

Eight Roads Ventures

Series B+ 4 investors entered at this stage

Nextech Invest

Casdin Capital

PFM Health Sciences

RA Capital Management

Blueprint Medicines mafia

Startups founded by Blueprint Medicines alumni

Former Blueprint Medicines employees who went on to start their own companies. Sorted by Dealroom signal score.

Solve TherapeuticsEst. 2021

Dave JohnsonUnited States

Signal score89

Nested TherapeuticsEst. 2021

Klaus HoeflichUnited States

Signal score68

Frontier MedicinesEst. 2018

Chris VarmaUnited States

Signal score65

Celsius TherapeuticsEst. 2018

Christoph LengauerUnited States

Signal score64

IDRxEst. 2022

Alexis BorisyUnited States

Signal score63

Recludix PharmaEst. 2019

Patrick ZarrinkarUnited States

Signal score61

Book a demo to explore the full alumni network →

Global footprint

Where Blueprint Medicines has talent and traffic

AI talent share

0.7% of workforce is AI talent
(5 of 741 staff)

Core AI20.27%

Other AI30.4%

Non-AI workforce73699.33%

Workforce by country

12 countries with
team presence

🇺🇸 United States85.9%

🇩🇪 Germany4%

🇨🇭 Switzerland3.7%

🇪🇸 Spain1.6%

🇮🇹 Italy1.4%

Top 5 of 12 shown

Web traffic by country

21K monthly visits
across markets

🇺🇸 United States63.8%

🇮🇳 India15.7%

🇨🇦 Canada5.7%

🇬🇧 United Kingdom3.8%

🇫🇷 France3.8%

Top 5 markets shown

Patent intelligence

$87M patent portfolio · 95 active families

Estimated portfolio value

$87M

1.1% of market cap · comparable to top peer Constellation Pharmaceuticals ($116M)

95 active patent families

Where Blueprint Medicines innovates Pharmaceutical medicinePyrimidineTautomerCombinatorial chemistryPharmaceutical Substances

Where Blueprint Medicines concentrates vs peers

Each axis is a top-10 topic across Blueprint Medicines and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Blueprint Medicines

An AI-synthesized read of the highest-engagement posts about Blueprint Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Blueprint Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles